What are the Rome IV criteria for diagnosing irritable bowel syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Rome IV Criteria for IBS

The Rome IV criteria require recurrent abdominal pain at least 1 day per week in the last 3 months (with symptom onset at least 6 months prior to diagnosis), associated with two or more of the following: improvement with defecation, onset associated with a change in stool frequency, or onset associated with a change in stool form. 1

Core Diagnostic Requirements

The Rome IV criteria represent an evolution from Rome III, with two critical changes that make the diagnosis more restrictive:

Primary Symptom Requirement

  • Abdominal pain must be present (the term "discomfort" was removed from Rome IV)
  • Pain frequency: at least 1 day per week (increased from 3 days per month in Rome III)
  • Duration: symptoms present for the past 3 months
  • Chronicity: symptom onset at least 6 months before diagnosis

Associated Features (Need ≥2 of 3)

  1. Pain improvement with defecation (suggests colonic origin)
  2. Pain onset associated with change in stool frequency (suggests altered intestinal transit)
  3. Pain onset associated with change in stool form/appearance (suggests altered intestinal transit)

Critical Distinction: Rome IV vs Rome III

The evidence shows that only 59-87% of Rome III IBS patients meet Rome IV criteria 2, 3. This is clinically significant because:

  • Rome IV-positive patients are more likely to be female, younger, and have more severe disease 2, 3
  • They demonstrate higher pain severity, greater bloating, more somatization, increased fatigue, and enhanced rectal sensitivity compared to Rome IV-negative patients 2
  • They have worse quality of life and more severe gastrointestinal symptoms 3
  • Psychological comorbidity severity (anxiety/depression) does not differ between groups 2

Common Pitfalls to Avoid

Do not diagnose IBS if:

  • Pain is continuous on every day of the week (this suggests functional abdominal pain syndrome, not IBS) 1
  • Symptoms have been present for less than 6 months (may represent transient post-infectious changes or evolving organic disease) 1
  • Pain is absent (painless bowel dysfunction is classified as functional constipation or functional diarrhea, not IBS) 1

Important caveats:

  • The 6-month symptom onset requirement distinguishes IBS from self-limited conditions like infections and allows time to diagnose progressive diseases like colorectal cancer 1
  • Symptoms typically occur intermittently with flares lasting 2-4 days followed by remission periods 1
  • Patients may report that symptoms began immediately after an acute gastroenteritis episode (post-infection IBS) 4

Supporting Symptoms (Not Required for Diagnosis)

While not part of the diagnostic criteria, these Manning criteria symptoms are commonly present and support the diagnosis:

  • Visible abdominal distension/bloating
  • Abnormal stool form (hard and/or loose)
  • Abnormal stool frequency (<3/week or >3/day)
  • Straining at defecation
  • Urgency
  • Feeling of incomplete evacuation
  • Passage of mucus per rectum 1

Clinical Performance of Rome IV Criteria

Recent validation studies demonstrate:

  • Sensitivity: 82-90% and Specificity: 85% when applied in secondary care 5
  • Positive likelihood ratio: 5.5-6.1 (strong evidence for disease when positive) 5
  • Negative likelihood ratio: 0.11-0.21 (strong evidence against disease when negative) 5

A 2025 study suggests that relaxing the pain frequency requirement back to 3 days per month (while keeping other Rome IV criteria) improves diagnostic performance with sensitivity of 90.2% and specificity of 85.1% 5. However, this modification is not yet officially adopted.

Rome V Update (2026)

The newest Rome V criteria have modified requirements again, though the evidence base is still emerging. Rome V appears to identify a clinically less severe cohort with lower symptom severity, less psychological comorbidity, and higher quality of life compared to Rome IV 6. The Rome V criteria are also less stable during longitudinal follow-up 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.